Business
NurExone Engages Investor Relations Service Provider
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Engages Investor Relations Service ProviderToronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the \"Company\" or \"NurExone\"), a biopharmaceutical company developing biologically-guided exosome therapy (\"ExoTherapy\") for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC (\"Litchfield\") to perform investor relations services and activities, as defined in accordance with the policies of the TSX Venture Exchange (\"TSXV\") and applicable securities laws.Pursuant to the agreement with Litchfield, the Company will pay an annual cash fee of USD$14,000, of which USD$5,000 is payable upon entering into the agreement, with the remaining amount payable in three equal installments over the following nine months. Certain investor relations services may also be billed on an ad hoc basis. The term of the agreement is for one year, subject to termination by NurExone at any time without penalty. Litchfield does not own or control any securities of the Company. Litchfield operates out of Lakeville, Connecticut and is engaged to publish equity research on the Company on 15 global financial platforms and target its research to institutional investors who are invested in similar companies.About NurExone Biologic Inc.NurExone Biologic Inc. is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the Company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.For further information, please contact:Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Inbar Paz-Benayoun, Adv. Head of Communications and Investor RelationsPhone: +972-52-3966695Email: [email protected] Relations (Canada)Phone: +1 905-347-5569Email: [email protected] FORWARD-LOOKING STATEMENTSThis press re...